Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

This trial is testing an intermittent dosing schedule for darolutamide — a hormone-blocking drug — when given alongside standard hormone therapy (ADT) and docetaxel chemotherapy for men with newly diagnosed metastatic hormone-sensitive prostate cancer (cancer that has spread but still responds to hormone lowering). **You may be eligible if...** - You are male, 18 or older, with a confirmed diagnosis of metastatic prostate cancer (spread to other parts of the body) - Your cancer is hormone-sensitive (has not yet become resistant to hormone therapy) - You are fit enough to receive ADT plus docetaxel chemotherapy - You have adequate bone marrow, kidney, and liver function **You may NOT be eligible if...** - Your prostate cancer has become castration-resistant (no longer responds to hormone lowering) - You have had prior treatments for metastatic disease - You have a serious heart condition or other illness that makes chemotherapy too risky - You are not willing or able to follow the study schedule Talk to your doctor to see if this trial is right for you.